Can Ursodeoxycholic Acid Cause Black Stool?
Ursodeoxycholic acid does not cause black (tarry) stools as a recognized adverse effect. Black tarry stools typically indicate upper gastrointestinal bleeding, which is not a documented side effect of UDCA therapy.
Common Gastrointestinal Side Effects of UDCA
The FDA-approved drug label and clinical evidence identify the following gastrointestinal adverse effects:
- Diarrhea or loose stools is the most commonly reported gastrointestinal side effect 1, 2
- Right upper abdominal pain may occur during therapy 2
- Gastrointestinal side effects were predominantly reported in clinical studies but none required hospitalization or ICU admission 3
What UDCA Actually Does to Bile Acids and Stool
- UDCA increases lithocholic acid excretion in stool (not serum), which is a normal metabolic pathway and does not cause black coloration 4
- UDCA becomes the predominant serum bile acid during therapy, replacing more toxic bile acids 4
Important Safety Considerations
Rare Gastrointestinal Complications
- Enteroliths (bezoars) have been reported in rare postmarketing cases, particularly in patients with intestinal stenosis or stasis (e.g., surgical enteroanastomoses, Crohn's disease), which can cause obstructive symptoms requiring surgical intervention 1
- If obstructive gastrointestinal symptoms develop, UDCA should be held until clinical evaluation is completed 1
Long-term Safety Profile
- UDCA has been used safely for up to 12 years without significant side effects in clinical studies 4
- A comprehensive pharmacovigilance study analyzing 1,651 adverse events from the FAERS database (2004-2023) did not identify black stools as a recognized adverse event 2
Clinical Pitfall to Avoid
If a patient on UDCA develops black tarry stools, investigate for gastrointestinal bleeding from another cause rather than attributing it to the medication. This is particularly important in patients with advanced liver disease who may develop complications such as esophageal varices—three patients with stage III/IV primary biliary cirrhosis experienced variceal hemorrhage during long-term UDCA therapy, though this was due to disease progression rather than drug toxicity 4.